Distribution Partnership Expands Industry Adoption and Standardization of Leading Fluorescence Agents and Imaging Applications
BEDFORD, Mass., Jan. 20 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc (CRi) and VisEn Medical announced today that they have signed a non-exclusive agreement to enable CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America. The distribution partnership is designed to broaden and extend today's leading fluorescence in vivo imaging technologies, applications and standards in research and drug development.
"With a deep heritage in multi-spectral fluorescence in vivo imaging and fluorescence microscopy imaging systems, we have built a significant customer base with a broad range of applications in life science research today. Bringing VisEn's fluorescent in vivo agents and labels to our Maestro(TM) multispectral fluorescence imaging system customers now expands the breadth of research for them, and for CRi," said George Abe, CRi's President and CEO. "We are pleased to be partnering with VisEn around their unparalleled agent products, and we look forward to continually expanding today's areas of in vivo research together."
VisEn's proprietary in vivo imaging agents and labels are designed to provide a robust and broad range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways in vivo, with several more new agents expected for launch in 2009. Key research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease, and pulmonary diseases, all in the context of the living animal. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag(R) fluorescence labeling dyes for custom in vivo agent development, and its NanoSpark(R) in vivo labeling nanoparticles, all designed and optimized specifically for superior brightness, biocompatibility, stability and results in in vivo imaging. VisEn's agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro(TM) system with its powerful proprietary multispectral imaging technology. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.
"We are pleased to be working with CRi to further extend the applications and markets for our collective suite of fluorescence imaging technologies," said Kirtland Poss, President and CEO of VisEn Medical. "With several applications already developed in oncology and inflammation using the VisEn agents on the Maestro platforms, we look forward to working with CRi in rapidly expanding today's research areas in fluorescence imaging in vivo."
About VisEn Medical Inc.
VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas.
Additional information can be found at www.visenmedical.com.
Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.
With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility. We are able to rapidly design and manufacture system-level solutions for a variety of growing market applications.
Learn more at www.cri-inc.com.
SOURCE VisEn Medical Inc.